Key facts
- This page summarizes Vaseem Mahboob's Form 4 filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Aug 2026, 17:56.
Vaseem Mahboob - 07 Aug 2026 Form 4 Insider Report for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- KMTS
- Reported as of
- 07 Aug 2026
- Net transaction value
- -$680,383
- SEC form
- 4
- Accepted by SEC
- 11 Aug 2026, 17:56:22 UTC
- Prior SEC filing
- 06 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vaseem Mahboob filed Form 4 for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) on 11 Aug 2026.
Change
- Previous filing in this sequence was filed on 06 Aug 2026.
- Current net transaction value: -$680,383.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001655157
Primary reporting owner
Mahboob Vaseem
- Relationship
- Chief Financial Officer
- Address
- 3933 LAKE WASHINGTON BLVD NE, SUITE 200, KIRKLAND
- Signature
- /s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob
- Signature date
- 11 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KMTS
transaction
Common Shares
Sale
- Transaction value
- $667,218
- Shares
- -25,787
- Change %
- -30%
- Price
- $25.87
- Shares after
- 61,109
- Date
- 07 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
KMTS
transaction
Common Shares
Sale
- Transaction value
- $13,165
- Shares
- -500
- Change %
- -0.82%
- Price
- $26.33
- Shares after
- 60,609
- Date
- 07 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2025.
Footnote F2
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.3100 to $26.3050. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Footnote F3
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.3150 to $26.3600. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.